Welcome to our dedicated page for BIONTECH news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BIONTECH stock.
BioNTech SE (NASDAQ: BNTX) generates frequent news flow as a global next generation immunotherapy company focused on oncology, mRNA technologies and COVID-19 vaccines. Its updates often cover progress across a diversified oncology pipeline that includes mRNA cancer immunotherapies, next-generation immunomodulators, antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T cell therapies, as well as developments in its mRNA vaccine programs for infectious diseases.
Investors following BioNTech news can expect regular announcements on clinical trial milestones in major tumor types such as lung, breast, gynecologic, gastrointestinal and genitourinary cancers. Recent releases have highlighted late-stage data readouts and trial initiations for investigational agents like pumitamig (a PD-L1xVEGF-A bispecific antibody co-developed with Bristol Myers Squibb) and gotistobart (a CTLA-4–targeting Treg modulator), including Phase 2 and Phase 3 results in indications such as triple-negative breast cancer and squamous non-small cell lung cancer.
BioNTech’s news stream also includes corporate and financial updates, such as quarterly results, guidance changes, and details of its cash and investment position. The company reports on its COVID-19 vaccine franchise, including launches of variant-adapted vaccines for specific vaccination seasons, and comments on how vaccine market dynamics affect revenues.
Another recurring theme in BNTX news is strategic transactions and partnerships. BioNTech has announced an all-stock acquisition of CureVac N.V. to strengthen its position in mRNA design, delivery formulations and manufacturing, and regularly issues releases on its collaboration with partners including Bristol Myers Squibb, Duality Biologics, OncoC4, Pfizer and others.
This news page aggregates these developments in one place, allowing readers to track BioNTech’s clinical progress, partnership activity, financial disclosures and strategic updates over time.
BioNTech (NASDAQ: BNTX) has appointed Ramón Zapata-Gomez as its new Chief Financial Officer, effective July 1, 2025. Zapata will succeed Jens Holstein, who will retire as planned on June 30, 2025. Zapata joins from Novartis AG, where he served as CFO of their global biomedical research organization since 2022.
With over 25 years of experience in pharmaceutical and consumer goods industries, Zapata brings extensive expertise in finance, M&A, and digital transformations. His appointment aligns with BioNTech's strategy to become a multi-product oncology company. In his new role, Zapata will focus on optimizing financial infrastructure, performance in key markets, and driving cost-effective value generation as the company prepares for oncology product launches.
BioNTech (NASDAQ: BNTX) will showcase data from its oncology pipeline at the AACR Annual Meeting in Chicago (April 25-30, 2025). The presentations will feature:
1. BNT327: A next-generation bispecific antibody showing superior anti-tumor activity in preclinical studies when combined with antibody-drug conjugates (ADCs)
2. BNT116: Phase 1 clinical trial data in combination with cemiplimab for non-small cell lung cancer (NSCLC), demonstrating anti-tumor activity and manageable safety profile
3. BNT314/GEN1059: Preclinical data showing enhanced anti-tumor activity when combined with PD-1 inhibition
The company's oncology portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, with over 20 active Phase 2 and 3 trials. Multiple data readouts are expected in 2025 and 2026.
BioNTech SE (Nasdaq: BNTX) has announced it will release its first quarter 2025 financial results on Monday, May 5, 2025. The company will host a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) to discuss the financial results and provide a corporate update.
Investors, financial analysts, and the public can access the conference call via telephone by registering through a provided link, which will supply dial-in numbers and a PIN. Registration is recommended at least one day in advance. The webcast and slide presentation will be accessible through the company's Investor Relations section, with a replay available for 30 days after the call.
BioNTech (BNTX) reported Q4 2024 revenues of €1.2 billion and full-year revenues of €2.8 billion, with a net loss of €0.7 billion for 2024. The company maintains a strong financial position with €17.4 billion in cash and investments as of December 31, 2024.
Key highlights include:
- Advanced oncology pipeline with over 20 active Phase 2 and 3 clinical trials
- Completed acquisition of Biotheus, securing control of BNT327 immunomodulator candidate
- Successfully launched JN.1 and KP.2-adapted COVID-19 vaccines
- 2025 revenue guidance of €1.7-2.2 billion
The decrease in revenues was primarily attributed to lower COVID-19 vaccine sales due to reduced market demand and write-downs by collaboration partner Pfizer. R&D expenses increased to €2.25 billion in 2024, focusing on advancing clinical studies for late-stage oncology candidates. The company expects multiple data readouts in 2025 and 2026, aiming to become a diversified multi-product oncology portfolio company by 2030.
BioNTech SE (Nasdaq: BNTX) has announced it will release its fourth quarter and full year 2024 financial results on Monday, March 10, 2025. The company will host a conference call and webcast at 8:00 a.m. EDT (1:00 p.m. CET) on the same day.
Investors, financial analysts, and the public can participate in the conference call by registering through a provided link to receive dial-in numbers and a PIN. The presentation slides and webcast audio will be accessible through another link and the company's website. A replay of the webcast will be available for 30 days after the call on BioNTech's website.
BioNTech (NASDAQ: BNTX) has completed the acquisition of Biotheus, a clinical-stage biotechnology company focused on antibody development for oncological and inflammatory diseases. The transaction, valued at $800 million plus potential milestone payments of up to $150 million, was primarily paid in cash with a small portion in BioNTech ADSs.
The acquisition strengthens BioNTech's oncology strategy by securing full global rights to BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, along with Biotheus' entire pipeline and antibody generation platform. Biotheus will become BioNTech's indirect Chinese subsidiary, providing local R&D capabilities and an advanced biologics manufacturing facility.
FAQ
What is the current stock price of BIONTECH (BNTX)?
What is the market cap of BIONTECH (BNTX)?
